A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Aneustat (OMN54) Administered on a Daily Oral Regimen in Patients With Advanced Cancer and Lymphomas

Trial Profile

A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Aneustat (OMN54) Administered on a Daily Oral Regimen in Patients With Advanced Cancer and Lymphomas

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2015

At a glance

  • Drugs OMN 54 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Omnitura Therapeutics
  • Most Recent Events

    • 07 Apr 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 07 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Sep 2013 Planned end date changed from 1 Aug 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top